Luiza Cristine Diniz Neri

Luiza Cristine Diniz Neri

Auto-generated profile, based on publicly available information

Luiza Cristine Diniz Neri


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Pablo SilvaPablo Silva
Pablo Silva
NBNayana Maria Medeiros Vilar Barbosa
Nayana Maria Medeiros Vilar Barbosa
JLJoandra Maísa Silva Leite
Joandra Maísa Silva Leite
LALarissa Pereira Alves
Larissa Pereira Alves
JAJéssica C. de Andrade
Jéssica C. de Andrade
LUCIANA SCOTTILUCIANA SCOTTI
LUCIANA SCOTTI
Major depressive disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier (BBB) penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.

1 January 2024
Verified
Book Chapter
Open access
MGMaria Clara Ferreira Gonçalves
Maria Clara Ferreira Gonçalves
AMAndré Luiz Leocádio De Souza Matos
André Luiz Leocádio De Souza Matos
BRBárbara Fernandes Araújo Rodrigues
Bárbara Fernandes Araújo Rodrigues
LNLuiza Cristine Diniz Neri
Luiza Cristine Diniz Neri
HPHugo Fernandes Oliveira Pires
Hugo Fernandes Oliveira Pires
Book Brazil in Advancing Pharmacotherapy and Clinical Pharmacy in Latin America Proceedings of the Fourth Brazilian Congress of Pharmacotherapy and Clinical Pharmacy doi: 10.62922/4cbffc ISBN: 978-65-983944-2-4 Editors Wallace Entringer Bottacin – ORCID | Lattes | Google Scholar Thaís Teles de Souza – ORCID | Lattes Walleri Christini Torelli Reis – ORCID | Lattes | Google […]

1 January 2024
Verified
Book Chapter
Open access
MGMaria Clara Ferreira Gonçalves
Maria Clara Ferreira Gonçalves
AMAndré Luiz Leocádio De Souza Matos
André Luiz Leocádio De Souza Matos
BRBárbara Fernandes Araújo Rodrigues
Bárbara Fernandes Araújo Rodrigues
LNLuiza Cristine Diniz Neri
Luiza Cristine Diniz Neri
HPHugo Fernandes Oliveira Pires
Hugo Fernandes Oliveira Pires
Book Brazil in Advancing Pharmacotherapy and Clinical Pharmacy in Latin America Proceedings of the Fourth Brazilian Congress of Pharmacotherapy and Clinical Pharmacy doi: 10.62922/4cbffc ISBN: 978-65-983944-2-4 Editors Wallace Entringer Bottacin – ORCID | Lattes | Google Scholar Thaís Teles de Souza – ORCID | Lattes Walleri Christini Torelli Reis – ORCID | Lattes | Google […]

28 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Pablo SilvaPablo Silva
Pablo Silva
NBNayana M. M. V. Barbosa
Nayana M. M. V. Barbosa
JLJoandra M. da Silva Leite
Joandra M. da Silva Leite
LALarissa P. Alves
Larissa P. Alves
JAJéssica C. de Andrade
Jéssica C. de Andrade
LUCIANA SCOTTILUCIANA SCOTTI
LUCIANA SCOTTI
Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers — such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, magnetic nanoparticles, and liposomes — and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.